National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Events (1)
- Antibiotics (2)
- Antimicrobial Stewardship (2)
- Blood Clots (1)
- Cardiovascular Conditions (1)
- Caregiving (1)
- Care Management (1)
- Children/Adolescents (2)
- Chronic Conditions (1)
- Decision Making (2)
- Digestive Disease and Health (1)
- Education (1)
- Elderly (1)
- (-) Healthcare Costs (12)
- Healthcare Utilization (1)
- Health Insurance (2)
- Heart Disease and Health (1)
- Home Healthcare (1)
- Medical Expenditure Panel Survey (MEPS) (1)
- (-) Medication (12)
- Neurological Disorders (1)
- Patient Safety (1)
- Policy (2)
- Practice Patterns (1)
- Prevention (1)
- Respiratory Conditions (1)
- Surgery (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 12 of 12 Research Studies DisplayedLeeds IL, DiBrito SR, Canner JK
Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn's disease.
This goal of this study was to assess the cost-effectiveness of extended prophylaxis in patients with Crohn's disease after abdominal surgery. A decision tree model was used to assess cost-effectiveness and cost-per-case averted with extended-duration venous thromboembolism prophylaxis following abdominal surgery. Results showed that extended prophylaxis in patients with Crohn's disease postoperatively is not cost-effective when the cumulative incidence of posthospital thrombosis remains less than 4.9%. These findings are driven by the low absolute risk of thrombosis in this population and the considerable cost of universal treatment.
AHRQ-funded; HS024547.
Citation: Leeds IL, DiBrito SR, Canner JK .
Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn's disease.
Dis Colon Rectum 2019 Nov;62(11):1371-80. doi: 10.1097/dcr.0000000000001461..
Keywords: Prevention, Digestive Disease and Health, Surgery, Healthcare Costs, Adverse Events, Patient Safety, Blood Clots, Decision Making, Medication
McClellan C, Fingar KR, Ali MM
AHRQ Author: McClellan C
Price elasticity of demand for buprenorphine/naloxone prescriptions.
In this study, using the IBM MarketScan(R) Commercial Claims and Encounters Database for individuals with employer-sponsored private health insurance coverage, the researchers examined the relationship between cost sharing and the number of buprenorphine/naloxone prescription fills using enrollee-level longitudinal fixed effects models.
AHRQ-authored.
Citation: McClellan C, Fingar KR, Ali MM .
Price elasticity of demand for buprenorphine/naloxone prescriptions.
J Subst Abuse Treat 2019 Nov;106:4-11. doi: 10.1016/j.jsat.2019.08.001..
Keywords: Medication, Healthcare Costs, Health Insurance
Shaker M, Greenhawt M
Cost-effectiveness of stock epinephrine autoinjectors on commercial aircraft.
This study examined the cost-effectiveness of commercial airlines stocking epinephrine autoinjectors on every plane versus the standard emergency kit epinephrine ampules. The study assumed the autoinjectors reduced fatality risk by 10%. They used a Markov movule with microsimulation over an 80-year time horizon and concluded that it was cost-effective with a low annual cost per passenger-at-risk of 8 cents.
AHRQ-funded; HS024599.
Citation: Shaker M, Greenhawt M .
Cost-effectiveness of stock epinephrine autoinjectors on commercial aircraft.
J Allergy Clin Immunol Pract 2019 Sep - Oct;7(7):2270-76. doi: 10.1016/j.jaip.2019.04.029..
Keywords: Healthcare Costs, Medication
Shaker M, Greenhawt M
Providing cost-effective care for food allergy.
This article discusses the cost-effectiveness of food allergy management strategies for children. Screening at-risk infants for peanut allergy in particular carries a risk of overdiagnosis and is not cost-effective. An evidence review of the literature using PubMed showed that cost-effective care could be optimized in minimizing delay in oral food challenges for at-risk patients and for school-age children to epinephrine pens available at reasonable cost.
AHRQ-funded; HS024599.
Citation: Shaker M, Greenhawt M .
Providing cost-effective care for food allergy.
Ann Allergy Asthma Immunol 2019 Sep;123(3):240-48.e1. doi: 10.1016/j.anai.2019.05.015..
Keywords: Healthcare Costs, Medication, Children/Adolescents
Selden TM, Abdus S, Miller GE
AHRQ Author: Selden TM, Abdus S, Miller GE
Decomposing changes in the growth of U.S. prescription drug use and expenditures, 1999-2016.
Data from the Medical Expenditure Panel Survey (MEPS) was examined to analyze factors associated with changes in prescription drug use and expenditures in the US from 1999 to 2016. There were large increases in prescription drug use during that period, with per capita utilization increasing by nearly half and per capita expenditures more than doubled. Treatment of long-term conditions was a large driver in the increases in medication use.
AHRQ-authored.
Citation: Selden TM, Abdus S, Miller GE .
Decomposing changes in the growth of U.S. prescription drug use and expenditures, 1999-2016.
Health Serv Res 2019 Aug;54(4):752-63. doi: 10.1111/1475-6773.13164..
Keywords: Healthcare Costs, Healthcare Utilization, Medical Expenditure Panel Survey (MEPS), Medication
Hung A, Slejko JF, Lugo A
Validating a budget impact model using payer insight and claims data: a framework and case study.
The goal of this study was to assess the face validity, internal verification, and predictive validity of a previously published model that assessed the budgetary impact of antidiabetic formulary changes. The authors found that the budget impact model overpredicted utilization in the year after the formulary changes, and that discoveries through the validation process improved the accuracy and transparency of the model.
AHRQ-funded; HS024857.
Citation: Hung A, Slejko JF, Lugo A .
Validating a budget impact model using payer insight and claims data: a framework and case study.
J Manag Care Spec Pharm 2019 Aug;25(8):913-21. doi: 10.18553/jmcp.2019.25.8.913..
Keywords: Healthcare Costs, Medication
Gong CL, Zangwill KM, Hay JW
Behavioral economics interventions to improve outpatient antibiotic prescribing for acute respiratory infections: a cost-effectiveness analysis.
Researchers sought to determine the cost-effectiveness of three behavioral economic interventions designed to reduce inappropriate antibiotic prescriptions for acute respiratory infections (ARIs). Provider education on guidelines for the appropriate ARI treatment is compared with suggested alternatives, which use computerized clinical decision support to suggest non-antibiotic treatment choices; accountable justification, which mandates free-text justification into the patient's electronic health record when antibiotics are prescribed; and peer comparison. The authors concluded that behavioral economics interventions can be cost-effective strategies for reducing inappropriate antibiotic prescriptions by reducing healthcare resource utilization.
AHRQ-funded; HS019913.
Citation: Gong CL, Zangwill KM, Hay JW .
Behavioral economics interventions to improve outpatient antibiotic prescribing for acute respiratory infections: a cost-effectiveness analysis.
J Gen Intern Med 2019 Jun;34(6):846-54. doi: 10.1007/s11606-018-4467-x..
Keywords: Antibiotics, Antimicrobial Stewardship, Medication, Practice Patterns, Healthcare Costs, Respiratory Conditions
Callaghan BC, Reynolds E, Banerjee M
Out-of-pocket costs are on the rise for commonly prescribed neurologic medications.
The purpose of this study was to determine out-of-pocket costs for neurologic medications in 5 common neurologic diseases. The investigators concluded that out-of-pocket costs for neurologic medications have increased considerably over the last 12 years, particularly for those in high-deductible health plans. Out-of-pocket costs vary widely both across and within conditions. They assert that to minimize patient financial burden, neurologists require access to precise cost information when making treatment decisions.
AHRQ-funded; HS022258.
Citation: Callaghan BC, Reynolds E, Banerjee M .
Out-of-pocket costs are on the rise for commonly prescribed neurologic medications.
Neurology 2019 May 28;92(22):e2604-e13. doi: 10.1212/wnl.0000000000007564.
.
.
Keywords: Health Insurance, Healthcare Costs, Medication, Neurological Disorders
Krah NM, Bardsley T, Nelson R
Economic burden of home antimicrobial therapy: OPAT versus oral therapy.
There is increasing evidence that outpatient parenteral antimicrobial therapy (OPAT) is overused for children and that outcomes with oral therapy are equivalent. The objective of this study was to compare economic burden between OPAT and oral therapy, accounting for direct and indirect costs and caregiver quality of life (QoL). The investigators concluded that the overall burden of OPAT was substantially higher than that of oral therapy, including higher direct and indirect costs and greater impact on caregiver QoL.
AHRQ-funded; HS023320.
Citation: Krah NM, Bardsley T, Nelson R .
Economic burden of home antimicrobial therapy: OPAT versus oral therapy.
Hosp Pediatr 2019 Apr;9(4):234-40. doi: 10.1542/hpeds.201-0193.
.
.
Keywords: Healthcare Costs, Children/Adolescents, Caregiving, Home Healthcare, Antimicrobial Stewardship, Antibiotics, Medication
Hung A, Mullins CD, Slejko JF
Using a budget impact model framework to evaluate antidiabetic formulary changes and utilization management tools.
This study projected cost savings to the TRICARE program from changes to the antidiabetic formulary and utilization management (UM) policies. Budgetary impacts for 3 years as projected using a Microsoft Excel spreadsheet. This model projected a savings of up to $43 million in the third year from revisions to the payer’s formulary.
AHRQ-funded; HS024857.
Citation: Hung A, Mullins CD, Slejko JF .
Using a budget impact model framework to evaluate antidiabetic formulary changes and utilization management tools.
J Manag Care Spec Pharm 2019 Mar;25(3):342-49. doi: 10.18553/jmcp.2019.25.3.342..
Keywords: Care Management, Elderly, Healthcare Costs, Medication, Policy
Shaker MS, Greenhawt MJ
Analysis of value-based costs of undesignated school stock epinephrine policies for peanut anaphylaxis.
Children experiencing anaphylaxis at school may lack access to a personal epinephrine device, prompting recent legislation permitting undesignated (eg, non-student specific) stock epinephrine autoinjector units at school. However, epinephrine device costs vary, and the cost-effectiveness of undesignated school stock epinephrine is uncharacterized to date. The objective of this study was to define value-based strategies for undesignated school stock epinephrine programs.
AHRQ-funded; HS024599.
Citation: Shaker MS, Greenhawt MJ .
Analysis of value-based costs of undesignated school stock epinephrine policies for peanut anaphylaxis.
JAMA Pediatr 2019 Feb;173(2):169-75. doi: 10.1001/jamapediatrics.2018.4275..
Keywords: Healthcare Costs, Education, Policy, Medication
Smith GH, Shore S, Allen LA
Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure.
This study examined how prescription costs can greatly impact decision-making in patients with serious medical conditions. Forty-nine patients with heart failure with reduced ejection fracture were recruited and interviewed about a drug sacrubitril-valsartan. The drug is considered effective but can be costly. Most patients (45/49) said they would take the medicine if the out-of-pocket cost was only $5 per month more than their current medication. But if the costs increased to $100 more per month then only 43% would switch to sacrubritil-valsartan. Only 20% of participants said their physician had discussed medication costs in the past year.
AHRQ-funded; HS026081.
Citation: Smith GH, Shore S, Allen LA .
Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure.
J Am Heart Assoc 2019 Jan 8;8(1):e010635. doi: 10.1161/jaha.118.010635..
Keywords: Healthcare Costs, Decision Making, Heart Disease and Health, Cardiovascular Conditions, Medication, Chronic Conditions